Low-dose CBD shows limited benefits but may still affect medications
Evaluating the pharmacokinetics, efficacy and safety of low-dose cannabidiol.
AI Summary
This review examined the pharmacokinetics, pharmacodynamics, safety, and therapeutic effects of low-dose CBD—defined as ≤2.5 mg/kg or ≤175 mg/day. Oral doses of up to 150 mg produced peak blood concentrations and overall exposure 5- to 100-fold lower than a typical therapeutic dose of Epidiolex. In healthy volunteers, the review found little evidence of physical or neurological effects at these lower doses, and no serious adverse events were reported.
The findings offer limited support for the effectiveness of over-the-counter CBD at low doses. Randomized trials found no benefit across measured outcomes in conditions including Parkinson’s disease, Crohn’s disease, pain, fibromyalgia, stress, ocular hypertension, or psoriasis. Some improvements were reported for selected outcomes involving sleep, alcohol craving and control, and multiple sclerosis, but these effects were not consistent across related measures or studies. Importantly, low-dose CBD interacted with THC and several medications, suggesting that users should discuss regular CBD use with a healthcare professional, especially when taking other drugs. Overall, the review concludes that low doses show very little evidence of biological effects or therapeutic value.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.